Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.61 |
| ▸ | RAB9A | P51151 | 10/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | F13A1 | P00488 | 1/20 | 0.56 |
| ▸ | TGM2 | P21980 | 1/20 | 0.56 |
| ▸ | TGM1 | P22735 | 1/20 | 0.56 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.55 |
| ▸ | RELA | Q04206 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | TEK | Q02763 | 2/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17667007 | 0.80 | RAB9A (0.69) | NPC1RAB9ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL17667010 | 0.80 | RAB9A (0.69) | NPC1RAB9ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL5038634 | 0.79 | RAB9A (0.66) | NPC1RAB9ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL22455502 | 0.79 | L3MBTL1 (0.66) | NPC1RAB9ASMN1; SMN2LMNANFKB1 | |
| SCHEMBL1067851 | 0.78 | TSHR (0.65) | NPC1RAB9ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL8234749 | 0.78 | RAB9A (0.62) | NPC1RAB9ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL20212003 | 0.78 | RAB9A (0.62) | NPC1RAB9ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL21808438 | 0.77 | TGM2 (0.44) | NPC1LMNAF13A1TGM2TGM1 | |
| SCHEMBL30685458 | 0.77 | TGM2 (0.44) | NPC1LMNAF13A1TGM2TGM1 | |
| SCHEMBL8104147 | 0.77 | RAB9A (0.58) | NPC1RAB9ASMN1; SMN2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331023-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2025-06-17 | — | — | US | disclosed |
| CN-112739695-B | Novel thiazole derivative and pharmaceutically acceptable salt thereof | 永进药品工业株式会社 | 2025-03-18 | — | — | CN | disclosed |
| US-12110299-B2 | Thiazole derivatives and pharmaceutically acceptable salts thereof | YUNGJIN PHARM. CO., LTD. (KR) | 2024-10-08 | — | — | US | disclosed |
| EP-3853225-B1 | N-(5-(3-(1-((THIAZOL-2-YL)AMINO)-1-OXOPROPAN-2-YL)PHENYL)PYRIDIN-2-YL)ACRYLAMIDE DERIVATIVES AS CDK7 INHIBITORS FOR THE TREATMENT OF CANCER | YUNGJIN PHARMACEUTICAL CO LTD (KR) | 2023-11-29 | — | — | EP | disclosed |
| EP-3853225-B1 | N-(5-(3-(1-((THIAZOL-2-YL)AMINO)-1-OXOPROPAN-2-YL)PHENYL)PYRIDIN-2-YL)ACRYLAMIDE DERIVATIVES AS CDK7 INHIBITORS FOR THE TREATMENT OF CANCER | YUNGJIN PHARMACEUTICAL CO LTD (KR) | 2023-11-29 | — | — | EP | disclosed |
| EP-3302448-B1 | SUBSTITUTED HETEROCYCLYL DERIVATIVES AS CDK INHIBITORS | AURIGENE ONCOLOGY LTD (IN) | 2023-10-25 | — | — | EP | disclosed |
| EP-3302448-B1 | SUBSTITUTED HETEROCYCLYL DERIVATIVES AS CDK INHIBITORS | AURIGENE ONCOLOGY LTD (IN) | 2023-10-25 | — | — | EP | disclosed |
| US-20230250062-A9 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2023-08-10 | — | — | US | disclosed |
| US-20230250062-A9 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2023-08-10 | — | — | US | disclosed |
| US-20230250062-A9 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2023-08-10 | — | — | US | disclosed |
| US-10689347-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2020-06-23 | — | — | US | disclosed |
| WO-2020060112-A1 | NOVEL THIAZOLE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | YUNGJIN PHARM. CO., LTD. (KR) | 2020-03-26 | — | — | WO | disclosed |
| US-20190091226-A1 | NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USE | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2019-03-28 | — | — | US | disclosed |
| EP-3424928-A1 | NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USE | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2019-01-09 | — | — | EP | disclosed |
| US-20180362471-A9 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-12-20 | — | — | US | disclosed |
| US-20180155293-A1 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-06-07 | — | — | US | disclosed |
| US-20180155293-A1 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-06-07 | — | — | US | disclosed |
| US-20180155293-A1 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-06-07 | — | — | US | disclosed |
| EP-3302448-A1 | SUBSTITUTED HETEROCYCLYL DERIVATIVES AS CDK INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016193939-A1 | SUBSTITUTED HETEROCYCLYL DERIVATIVES AS CDK INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250062-A9 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | CDK19, CDK9, CDK1 | NPC1 3851/4885RAB9A 1346/4885SMN1; SMN2 1062/4885 |
| US-20180362471-A9 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | CDK19, CDK17, CDK1 | NPC1 3824/4885RAB9A 1572/4885SMN1; SMN2 1068/4885 |
| US-20180155293-A1 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | CDK19, CDK17, CDK1 | NPC1 3824/4885RAB9A 1572/4885SMN1; SMN2 1068/4885 |
| US-10689347-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | CDK19, CDK9, CDK1 | NPC1 3851/4885RAB9A 1346/4885SMN1; SMN2 1062/4885 |
| US-12331023-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | CDK19, CDK9, CDK1 | NPC1 3851/4885RAB9A 1346/4885SMN1; SMN2 1062/4885 |
| US-12110299-B2 | Thiazole derivatives and pharmaceutically acceptable salts thereof | CDKL1, CDK4, CDKL3 | NPC1 2287/4885RAB9A 2512/4885SMN1; SMN2 2191/4885 |
| US-20190091226-A1 | NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USE | ERBB2, EGFR, ERBB4 | NPC1 2217/4885RAB9A 1468/4885SMN1; SMN2 3422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.